Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Safety Clinical Trials Drug Pricing Weight Loss Cancer Treatment Drug Regulation Medications Weight Loss Drugs

3 ARTICLES

yesterday

Postpartum GLP‑1 Starts Surge in U.S., Rising More Than 20‑Fold by Early 2025

Researchers say the rapid uptake has outpaced safety evidence on breastfeeding and infant outcomes, prompting calls for focused study and stronger monitoring.

5 ARTICLES

yesterday

Sanofi Expands Regeneron Collaboration With $1 Billion Upfront for Four Antibody Programs

40 ARTICLES

2d ago

Retatrutide Drives Record Weight Loss in Type 2 Diabetes, Company Moves Toward U.S. Filing

4 ARTICLES

2d ago

Orforglipron Found Noninferior to Insulin Glargine for Major Heart Events

4 ARTICLES

2d ago

U.S. Spending on GLP‑1 Drugs Rises to $64.9 Billion as Patient Costs Bite

13 ARTICLES

3d ago

FDA Elevates Inventia Chlorthalidone Recall to Class II After Failed Dissolution Tests

8 ARTICLES

4d ago

Capricor Faces Multiple Securities Suits After FDA Flags Unapproved Changes to Trial Analysis

7 ARTICLES

last wk.

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

3 ARTICLES

last wk.

Polypharmacy Rises and One in Five Seniors Face Major Drug‑Interaction Risk

5 ARTICLES

last wk.

Nanexa Licenses PharmaShell to Novo Nordisk in Deal Worth Up to €1.17 Billion

4 ARTICLES

last wk.

U.S. Lawsuits and European Finding Focus Scrutiny on GLP‑1 Drugs and Rare Vision Loss

3 ARTICLES

last wk.

Acadia’s Alzheimer’s Psychosis Drug Misses Mid‑Stage Goal

23 ARTICLES

last wk.

Overton Sidesteps Questions at Senate FDA Confirmation Hearing

Pharmaceuticals

Postpartum GLP‑1 Starts Surge in U.S., Rising More Than 20‑Fold by Early 2025

Sanofi Expands Regeneron Collaboration With $1 Billion Upfront for Four Antibody Programs

Retatrutide Drives Record Weight Loss in Type 2 Diabetes, Company Moves Toward U.S. Filing

Orforglipron Found Noninferior to Insulin Glargine for Major Heart Events

U.S. Spending on GLP‑1 Drugs Rises to $64.9 Billion as Patient Costs Bite

FDA Elevates Inventia Chlorthalidone Recall to Class II After Failed Dissolution Tests

AstraZeneca Buys Stake in Summit to Pursue Cancer Drug Combinations

Kodiak Drugs Clear Phase 3 for Wet AMD and Shares Soar

FDA Approves Juvmo as First D1/D5 Agonist for Parkinson’s Disease

Lilly’s Foundayo Wins Early Market Share as Company Moves to Scale Production

Never miss stories about

Pharmaceuticals

Lilly Pulls Ahead in GLP‑1 Market as Novo Confronts U.S. Headwinds

FDA Upgrades Vitruvias Thyroid Tablet Recall to Highest-Risk Class

Overton Dodges Key Science Questions at Senate FDA Hearing

Capricor Faces Multiple Securities Suits After FDA Flags Unapproved Changes to Trial Analysis

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

Polypharmacy Rises and One in Five Seniors Face Major Drug‑Interaction Risk

Nanexa Licenses PharmaShell to Novo Nordisk in Deal Worth Up to €1.17 Billion

U.S. Lawsuits and European Finding Focus Scrutiny on GLP‑1 Drugs and Rare Vision Loss

Acadia’s Alzheimer’s Psychosis Drug Misses Mid‑Stage Goal

Overton Sidesteps Questions at Senate FDA Confirmation Hearing

Never miss stories about

Pharmaceuticals